Findings

What do systematic reviews say?

1 questions · 1 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment

Overall survival: Median length of · stage III and IV cutaneous melanoma

It is very uncertain whether neoadjuvant targeted treatment (BRAF/MEK inhibition) changes overall survival (OS), measured by number of deaths over time,Median compared with no neoadjuvant treatment (very low certainty).

1 finding from 1 review

Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
HR 0.28 [0.03, 2.25]
1 study · 21 participants
Very low